Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Stuttgart - Delayed Quote EUR

Innovent Biologics, Inc. (6IB.SG)

Compare
4.8400
-0.0600
(-1.22%)
As of 8:09:05 AM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 6IB.SG

Recent News: 6IB.SG

View More
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire yesterday
NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer

NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer
PR Newswire 8 days ago
Q Technology (Group) And 2 More Stocks That May Be Trading Below Estimated Value

Q Technology (Group) And 2 More Stocks That May Be Trading Below Estimated Value
Simply Wall St. 10 days ago
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
PR Newswire 15 days ago
Exploring High Growth Tech And 2 Other Prominent Stocks With Potential

Exploring High Growth Tech And 2 Other Prominent Stocks With Potential
Simply Wall St. 26 days ago
CDE grants BTD to Innovent’s IBI343 for pancreatic cancer

CDE grants BTD to Innovent’s IBI343 for pancreatic cancer
Pharmaceutical Technology last month
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
PR Newswire last month
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire last month
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
PR Newswire last month
High Growth Tech Stocks Innovent Biologics And 2 Other Promising Picks

High Growth Tech Stocks Innovent Biologics And 2 Other Promising Picks
Simply Wall St. last month
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference

Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire last month
View More

Related Tickers

196170.KQ ALTEOGEN Inc.
400,000.00
+3.36%
 
MGNX MacroGenics, Inc.
2.2800
-7.32%
 
IPA ImmunoPrecise Antibodies Ltd.
0.3292
-4.08%
 
DNA Ginkgo Bioworks Holdings, Inc.
8.01
-2.79%
 
RXRX Recursion Pharmaceuticals, Inc.
6.59
-12.25%
 
MRNA Moderna, Inc.
30.27
-2.23%